New Kidney Cancer Treatment Shows Promise in Phase 2
Patients with a rare form of kidney cancer saw a 35 percent response rate to a new drug combination in a recent study.
Updated on Oct. 24, 2026 in Cancer
A phase 2 study shows that the combination of lenvatinib and pembrolizumab shows antitumor activity in patients with metastatic chromophobe renal cell carcinoma. The treatment achieved an objective response rate of 35 percent in the study group.
Why it matters
Chromophobe renal cell carcinoma is a rare form of kidney cancer that accounts for about 5 percent of all cases. This study provides new data on a potential first-line treatment approach for those with metastatic disease.
In a phase 2 trial of 20 patients with metastatic chromophobe renal cell carcinoma, researchers observed a 35 percent objective response rate against a predefined efficacy threshold of 30 percent. While the results are promising, longer follow-up is necessary to assess the durability of outcomes.
The players
ESMO
The European Society for Medical Oncology is a professional organization focused on advancing oncology practice through research and education.
The details
The treatment protocol combines 20 mg of oral lenvatinib daily with 200 mg of intravenous pembrolizumab every three weeks. Lenvatinib acts as a multikinase inhibitor to block tumor growth signals, while pembrolizumab is an immunotherapy agent that helps the immune system identify and attack cancer cells. During the study, clinicians managed treatment toxicities, including grade 3 adverse events in six patients, through dose reductions and scheduled interruptions.
Timeline
October 23, 2026: Results presented at the ESMO Congress 2026.
Health Landscape
This study follows a pattern set by the ESMO Congress in highlighting new developments in oncology research. It addresses a significant gap in treatment for a rare condition where standard therapeutic options remain limited.
Patients diagnosed with rare kidney cancers should speak with their oncology team about whether clinical trials or emerging combinations like this are appropriate for their specific disease profile. Because chromophobe renal cell carcinoma is distinct from other kidney cancers, individual treatment plans require expert, evidence-based guidance.
The takeaway
This preliminary study indicates that lenvatinib plus pembrolizumab may provide a viable option for metastatic chromophobe renal cell carcinoma. Patients and their caregivers should track updates on this treatment's long-term outcomes and discuss with an oncologist if such therapies align with current care standards.
Further reading
Learn more about emerging research and clinical developments in Cancer.
Source note: This article includes information reported by Urotoday.
